Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Golimumab in both biologic naive (BN) and biologic experienced (BE) patients with active ulcerative colitis.

Next Previous
Search
Trial Profile

Efficacy and safety of Golimumab in both biologic naive (BN) and biologic experienced (BE) patients with active ulcerative colitis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 06 Dec 2017 New trial record
  • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top